Experimental combo for skin cancer stalls as trial ends early

NCT ID NCT04913220

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug (SAR444245) combined with an existing immunotherapy (cemiplimab) in 46 adults with advanced melanoma or squamous cell skin cancer that could not be surgically removed. The goal was to see if the combination shrank tumors. However, the study was terminated early, so we have limited information on how well it worked or its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SAR444245 (THOR-707) combined with cemiplimab (Libtayo)

What this could lead to

If it had succeeded, this combination might have offered a new treatment option for people with advanced skin cancers that cannot be removed by surgery.

What could go wrong

The trial was terminated early, so we have very little data on whether the combination works or is safe. It is also a small, early-phase study, so even if completed, results would not be conclusive.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT MELANOMA SQUAMOUS CELL CARCINOMA OF SKIN

Contacts and locations

Show contact details

Locations

Beverly Hills Cancer Center & Optima Diagnostic Imaging Site Number : 8400007

Beverly Hills, California, 90211, United States
Investigational Site Number : 0360001

Macquarie University, New South Wales, 2109, Australia
Investigational Site Number : 1520001

Santiago, Reg Metropolitana de Santiago, 8420383, Chile
Investigational Site Number : 1520002

Santiago, Reg Metropolitana de Santiago, 7500921, Chile
Investigational Site Number : 1520003

Temuco, 4800827, Chile
Investigational Site Number : 1520004

Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520005

Santaigo, Reg Metropolitana de Santiago, 8241470, Chile
Investigational Site Number : 1520006

Antofagasta, 1420000, Chile
Investigational Site Number : 2500001

Nantes, 44093, France
Investigational Site Number : 2500002

Dijon, 21079, France
Investigational Site Number : 2500003

Bobigny, 93009, France
Investigational Site Number : 2500005

Lille, 59037, France
Investigational Site Number : 2500006

Pierre-Bénite, 69495, France
Investigational Site Number : 2760001

Hamburg, 20246, Germany
Investigational Site Number : 2760003

Mannheim, 68167, Germany
Investigational Site Number : 2760004

Berlin, 10117, Germany
Investigational Site Number : 2760005

München, 80337, Germany
Investigational Site Number : 2760006

Minden, 32429, Germany
Investigational Site Number : 3800001

Naples, 80131, Italy
Investigational Site Number : 3800004

Perugia, 06126, Italy
Investigational Site Number : 7240001

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number : 7240002

Santander, Cantabria, 39008, Spain
Investigational Site Number : 7240003

L'Hospitalet de Llobregat, Barcelona [Barcelona], 08908, Spain
Investigational Site Number : 7240004

Barcelona, Barcelona [Barcelona], 08036, Spain